Eyevensys Appoints Patricia Zilliox, PhD, as Chief Executive Officer
Tuesday, December 12, 2017 | Management/Leadership
Eyevensys, a clinical stage biotech company developing non-viral gene therapies for ophthalmic diseases, announced the appointment of Patricia Zilliox. PhD, as CEO.
Dr. Zilliox, who joined the Eyevensys board in May 2016, has more than 25 years of global clinical development expertise. She previously served as Chief Drug Development Officer of the Clinical Research Institute, a division of the Foundation Fighting Blindness, in Columbia, Maryland. From late 2008 until May 2011, Dr. Zilliox was head of clinical development at Alcon Laboratories, managing clinical development programs in areas of eye diseases such as glaucoma, allergy, dry eye, infectious diseases of the eye, and retinal diseases such as dry- and wet AMD. Dr. Zilliox previously worked for Alcon in Paris, France, where she was responsible for the execution of Alcon’s European ophthalmology clinical trials.
"I am delighted that Patricia has agreed to become the company’s new CEO. Patricia’s strong clinical development experience in the field of ophthalmology together with her expertise at the Foundation Fighting Blindness will be important assets in building significant value for Eyevensys and its unique proprietary EyeCET technology. I am confident in Patricia’s ability to enhance and execute the company's strategic plan to bring new medicines to market and create value for the Company’s shareholders," Garth Cumberlidge, Chairman of Eyevensys’ Board, said in a company news release. “On behalf of Eyevensys board, I would also like to take this opportunity to thank Raffy Kazandjian for nurturing Eyevensys from its formative days to a clinical stage company.”
“It is a pleasure to become the CEO of a company I already know well and one that combines world-class scientific innovation, unique technology with significant commercial potential and a team of experts in the field of ophthalmology who are committed to bringing innovative products to ophthalmic patients," Dr. Zilliox said in the news release. "I am looking forward to leading our efforts to further the clinical development of our lead product EYS606 and to develop a strong portfolio of proprietary products to treat major ophthalmic diseases leveraging our unique EyeCET platform."
You must be logged in to leave a comment.